BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK
793 results:

  • 1. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
    Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
    Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical, Morphological and Molecular Features of Spitz tumors.
    Donati M; Mansour B; Hagstrom M; Gerami P; Kazakov DV
    Cesk Patol; 2024; 60(1):35-48. PubMed ID: 38697826
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to alk inhibitors in alk-mutant neuroblastoma.
    Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
    Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. alk upregulates POSTN and WNT signaling to drive neuroblastoma.
    Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
    Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Spitz melanocytic neoplasms with MLPH::alk fusions: Report of two cases with previously unreported features and literature review.
    Salah HT; Yang RK; Roy-Chowdhuri S; Ross MI; Aung PP; Rothrock AT; Torres-Cabala CA; Curry JL; Prieto VG; Nagarajan P; Cho WC
    J Cutan Pathol; 2024 Jun; 51(6):407-414. PubMed ID: 38444194
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. An Infant-Type Hemispheric Glioma With SOX5::alk: A Novel Fusion.
    Tsai CC; Huang MH; Fang CL; Hsieh KL; Hsieh TH; Ho WL; Chang H; Tsai ML; Kao YC; Miser JS; Wong TT; Su MY; Liu YL
    J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394779
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Parental occupations at birth and risk of adult testicular germ cell tumors in offspring: a French nationwide case-control study.
    Paul A; Danjou AMN; Deygas F; Guth M; Coste A; Lefevre M; Dananché B; Kromhout H; Spinosi J; Béranger R; Pérol O; Boyle H; Hersant C; Loup-Cabaniols V; Veau S; Bujan L; Olsson A; Schüz J; Fervers B; Charbotel B
    Front Public Health; 2023; 11():1303998. PubMed ID: 38292387
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single-center retrospective study.
    Schoeman S; Bagatell R; Cahill AM; Maris J; Mattei P; Mosse Y; Pogoriler J; Srinivasan A; Acord M
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30887. PubMed ID: 38291721
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Evaluation of Immunohistochemical Expression of alk-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
    Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.
    Wienke J; Visser LL; Kholosy WM; Keller KM; Barisa M; Poon E; Munnings-Tomes S; Himsworth C; Calton E; Rodriguez A; Bernardi R; van den Ham F; van Hooff SR; Matser YAH; Tas ML; Langenberg KPS; Lijnzaad P; Borst AL; Zappa E; Bergsma FJ; Strijker JGM; Verhoeven BM; Mei S; Kramdi A; Restuadi R; Sanchez-Bernabeu A; Cornel AM; Holstege FCP; Gray JC; Tytgat GAM; Scheijde-Vermeulen MA; Wijnen MHWA; Dierselhuis MP; Straathof K; Behjati S; Wu W; Heck AJR; Koster J; Nierkens S; Janoueix-Lerosey I; de Krijger RR; Baryawno N; Chesler L; Anderson J; Caron HN; Margaritis T; van Noesel MM; Molenaar JJ
    Cancer Cell; 2024 Feb; 42(2):283-300.e8. PubMed ID: 38181797
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. alk signaling primes the DNA damage response sensitizing alk-driven neuroblastoma to therapeutic ATR inhibition.
    Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
    Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Update on Selected High-grade Renal cell Carcinomas of the Kidney: FH-deficient, alk-rearranged, and Medullary Carcinomas.
    Chen YB
    Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
    Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
    JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. alkemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma.
    Ruella M
    Cancer Cell; 2023 Dec; 41(12):2016-2018. PubMed ID: 38086334
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study.
    Jiang K; Cao F; Yin L; Hu Y; Zhao X; Huang X; Ma X; Li J; Lu M; Sun Y
    J Endocrinol Invest; 2024 May; 47(5):1251-1260. PubMed ID: 38060154
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. alk inhibitors increase alk expression and sensitize neuroblastoma cells to alk.CAR-T cells.
    Bergaggio E; Tai WT; Aroldi A; Mecca C; Landoni E; Nüesch M; Mota I; Metovic J; Molinaro L; Ma L; Alvarado D; Ambrogio C; Voena C; Blasco RB; Li T; Klein D; Irvine DJ; Papotti M; Savoldo B; Dotti G; Chiarle R
    Cancer Cell; 2023 Dec; 41(12):2100-2116.e10. PubMed ID: 38039964
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of alk Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.
    Galiger C; Zohora FT; Dorneburg C; Tews D; Debatin KM; Beltinger C
    BMC Cancer; 2023 Nov; 23(1):1148. PubMed ID: 38007466
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identification of
    Aktaş TÇ; Kızmazoğlu D; Aktaş S; Gökbayrak ÖE; Serinan E; Erol A; Altun Z; Yuan H; Olgun HN
    Technol Cancer Res Treat; 2023; 22():15330338231211138. PubMed ID: 37964559
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression.
    Pflug KM; Lee DW; Tripathi A; Bankaitis VA; Burgess K; Sitcheran R
    Mol Pharm; 2023 Dec; 20(12):6140-6150. PubMed ID: 37939020
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 40.